ScienceDirect® Home Skip Main Navigation Links
You have guest access to ScienceDirect. Find out more.
 
Home
Browse
My Settings
Alerts
Help
 Quick Search
 Search tips (Opens new window)
    Clear all fields    
Pharmacology & Therapeutics
Volume 111, Issue 3, September 2006, Pages 808-835
 
Font Size: Decrease Font Size  Increase Font Size
 Abstract - selected
Article
Purchase PDF (1159 K)

Article Toolbox
 
 
 
Related Articles in ScienceDirect
View More Related Articles
 
View Record in Scopus
 
doi:10.1016/j.pharmthera.2006.01.002    
How to Cite or Link Using DOI (Opens New Window)

Copyright © 2006 Elsevier Inc. All rights reserved.

A comprehensive review and analysis of 25 years of data from an in vivo canine model of sudden cardiac death: Implications for future anti-arrhythmic drug development

Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

George E. BillmanCorresponding Author Contact Information, a, E-mail The Corresponding Author

aDepartment of Physiology and Cell Biology, The Ohio State University, 304 Hamilton Hall, 1645 Neil Avenue, Columbus, OH 43210-1218, United States


Available online 17 February 2006.

Abstract

Sudden cardiac death resulting from ventricular tachyarrhythmias remains the leading cause of death in industrially developed countries, accounting for between 300,000 and 500,000 deaths each year in the United States. Yet, despite the enormity of this problem, the development of safe and effective anti-arrhythmic agents remains elusive. The identification of effective anti-arrhythmic agents is critically dependent upon the use of appropriate animal models of human disease. During the last 25 years, a canine model of sudden cardiac death has proven to be useful in both the identification of factors contributing to ventricular fibrillation (VF) and the evaluation of potential anti-arrhythmic therapies. The present review provides a detailed retrospective analysis of the data obtained with this model. Briefly, VF was reliably and reproducibly induced by the combination of acute myocardial ischemia at site distant from a previous myocardial infarction during submaximal exercise (to activate the autonomic nervous system). This exercise plus ischemia test identified 2 stable populations of dogs: those that development malignant arrhythmias (susceptible, n = 303) and those that rarely developed even single premature ventricular activation (resistant, n = 209). The susceptible animals exhibited an elevated sympathetic activation (due to an enhanced β2-adrenoceptor responsiveness) and a subnormal parasympathetic regulation. Several interventions have proven to be particularly effective in preventing VF in the susceptible dogs; including calcium channel antagonists, left stellate ganglion disruption, ATP-sensitive potassium channel antagonists, β-adrenoceptor antagonists, and non-pharmacological interventions (endurance exercise training and dietary omega-3 fatty acids).

Keywords: Ventricular fibrillation; Myocardial ischemia; Myocardial infarction; Heart rate variability; Autonomic nervous system; Calcium channel antagonists; ATP-sensitive potassium channel antagonists

Abbreviations: CBF, coronary blood flow; LVP, left ventricular pressure; QTc, QT interval corrected for heart rate; Vcf, velocity of circumferential fiber shortening; VF, ventricular fibrillation

Article Outline

1. Introduction
2. A canine model of ventricular fibrillation
3. Characteristics of the model
3.1. Hemodynamic responses
3.2. Electrocardiographic responses
3.3. Alterations in cardiac autonomic responses
4. Effect of pharmacological interventions
4.1. Autonomic interventions
4.1.1. Parasympathetic interventions
4.1.2. Sympathetic interventions
4.2. Interventions that alter intracellular calcium
4.3. ATP-sensitive potassium channel antagonists
4.4. Other potassium channel antagonists
5. Non-pharmacological interventions
5.1. Effect of endurance exercise training
5.2. Effect of omega-3 fatty acids (fish oil)
6. Summary and conclusions: lessons learned and future directions
Acknowledgements
References































Corresponding Author Contact InformationTel.: +1 614 292 5189; fax: +1 614 2924888.

Pharmacology & Therapeutics
Volume 111, Issue 3, September 2006, Pages 808-835
 
Home
Browse
My Settings
Alerts